 |
The effects of
gemfibrozil and ciprofibrate on fibrinogen and CRP were studied in 99 patients with
primary hyperlipidemia (type IIa or IIb; total cholesterol $250 mg/dL). Patients
were randomized to gemfibrozil 600 mg twice daily or to ciprofibrate 100 mg once daily for
12 weeks. Both fibrates significantly reduced plasma fibrinogen levels, with somewhat
greater reductions observed in the ciprofibrate group. For both fibrates, the
fibrinogen-lowering effect was not associated with the lipid-lowering effect. At 6 weeks,
plasma CRP levels were significantly reduced by gemfibrozil but not ciprofibrate, but CRP
returned to baseline values at 12 weeks in both treatment groups. Reference:
de Maat MPM, Knipscheer HC, Kastelein JJP, Kluft C. Modulation of plasma fibrinogen levels
by ciprofibrate and gemfibrozil in primary hyperlipidaemia. Thromb Haemost 1997;77:75-79.
Web
site |
